Shots:
The US FDA has approved Aptar’s Cardamyst (Etripamil), developed by Milestone Pharmaceuticals, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults
Cardamyst (Intranasal) is a Bidose (BDS) Liquid Nasal Spray System
Aptar collaborated with Milestone Pharmaceuticals to design a custom polypropylene container closure system with an…
